6-K filed Jul 27, 2026 at 06:03 ET
argenx announced a definitive agreement to acquire Forte Biosciences for $77 per share in cash, a total equity value of approximately $2.2 billion, adding the first-in-class anti-CD122 antibody FB102 to its immunology pipeline. The acquisition, funded entirely from cash on hand and expected to close in Q3 2026, provides argenx with a pipeline-in-a-product opportunity with clinical proof-of-concept in vitiligo and celiac disease, broadening its portfolio beyond FcRn biology into T-cell and NK-cell mediated autoimmune diseases. The deal represents a strategic bolt-on that strengthens argenx's long-term growth narrative without diluting shareholders or adding debt.